NEW YORK (GenomeWeb) – Cancer diagnostics firm Biodesix has raised $8.6 million in promissory notes, according to a document filed recently with the US Securities and Exchange Commission.
The firm disclosed that it seeks to raise up to $20 million and that it has so far raised $8.6 million in promissory notes convertible into equity securities.
The firm did not disclose what it would use the funds for or the identities of the investors in the financing. It said that 18 investors have participated in the financing. Biodesix did not respond to requests seeking comment.